

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

DATE MAILED: 12/22/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/656,561	09/07/2000	Chennur Radhakrishna Reddy	11378.21US01	2020
23552	7590 12/22/2003	EXAMINER		INER
MERCHANT & GOULD PC P.O. BOX 2903 MINNEAPOLIS, MN 55402-0903			MCCORMICK, SUSAN B	
			ART UNIT	PAPER NUMBER
			1661	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/656,561	REDDY ET AL.			
Office Action Summary	Examiner	Art Unit			
	Susan B. McCormick	1661			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on <u>06 Au</u>	iaust 2003				
	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-18</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. §§ 119 and 120					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
13) Acknowledgment is made of a claim for domestic since a specific reference was included in the firs 37 CFR 1.78.	priority under 35 U.S.C. § 119(e	e) (to a provisional application)			
a) The translation of the foreign language provisional application has been received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.					
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413) Paper No(s)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)		atent Application (PTO-152)			

Art Unit: 1661

## **Detailed Action**

The amendment and Request for Continued Examination of August 6, 2003 has been received and entered.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

#### Request for Continued Examination

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after advisory action. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on August 6, 2003 has been entered.

#### **Declaration**

The declaration has been acknowledged and entered on August 6, 2003.

#### 35 U.S.C. § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Specifically:

In claim 1, line 4 and claim 5 are not clear as to what "domestic" stands for, Clarification is needed.

Claim 1, step (a) the term "finally" is confusing. Are the detergent and povidine iodine treatments simultaneous or sequential?

In claim 1, step (d) and claim 8 the recitation "each embedded block" has no antecedent basis.

In claim 1, step (d), claim 13 and claim 15 the term "somatic embryogenesis" is not clear as to what Applicant means. As discussed previously (paper no.9, pg. 4), algae do not produce embryos. Therefore, the meaning of "somatic embryogenesis" is unclear.

Claim 1, step (d), the term "filamentous callus" is unclear since callus are unorganized cells. If tissue is filamentous, it would appear not to be callus. Clarification is needed.

Claim 8, Applicant states "the calli" but it is unclear which type of callus is intended. Claim 1 has callus, pigmented callus or filamentous callus. Clarification is needed.

Art Unit: 1661

Claim 15 is indefinite as the term "enhanced" is still not clear as to what is the nature of the enhancement is, as previously stated (paper no. 6, p. 2).

In claims 16 and 17, the claim indicates that something different from the parent plant is obtained, i.e. faster growing plants. This is contrary to claim 1, wherein the preamble says "clonal propagating," which means that the same exact genetic duplicate is created. Therefore, these are improper dependent claims.

#### **Summary**

No claim is allowed. All claims are free of the prior art as there was no step taught where callus tissue is submerged in the agar plates therefore there was no suggestion to do it.

### Correspondence

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Susan B. McCormick-Ewoldt whose telephone number is (703) 305-1682. The Examiner can normally be reached Monday through Thursday from 6:00 a.m. to 4:30 p.m.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Bruce Campell, can be reached on (703) 308-4205. The official fax number for the group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Matrix Customer Service Center whose telephone number is (703) 308-0196.

sbm

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600